[1] 于淙,欧阳天佐,周培. 预测发热伴血小板减少综合征致死相关危险因素的meta分析[J]. 国际医药卫生导报,2020,26(14):2054-2063. DOI:10.3760/cma.j.issn.1007- 1245. 2020.14.019.
[2] Strzelczyk A, Schwab C, Knake S, et al. Reply to: "All patients with epilepsy, whether at high or low risk of SUDEP, should have access to individually tailored SUDEP information" by Oliver Henning, Karl O. Nakken, and Morten I. Lossius[J]. Epilepsy Behav, 2022, 127:108534. DOI: 10.1016/j.yebeh.2021.108534.
[3] Sato R, Ohmori K, Umetsu M, et al. An atlas of the quantitative protein expression of anti-epileptic-drug transporters, metabolizing enzymes and tight junctions at the blood–brain barrier in epileptic patients[J]. Pharmaceutics, 2021, 13(12): 2122. DOI: 10.3390/pharmaceutics13122122.
[4] Ji Z, Yin L, Li Y, et al. Development and validation of a liquid chromatography tandem mass spectrometry method with triple stage fragmentation to determine levetiracetam in epileptic patient serum and its application in therapeutic drug monitoring[J]. J Sep Sci, 2021, 44(23): 4255-4263. DOI: 10.1002/jssc.202100639.
[5] Cines DB, Liebman H, Stasi R. Pathobiology of secondary immune thrombocytopenia[J]. Semin Hematol, 2009, 46(1 Suppl 2):S2-S14. DOI: 10.1053/j.seminhematol. 2008.12.005.
[6] Kohli R, Chaturvedi S. Epidemiology and clinical manifestations of immune thrombocytopenia[J]. Hamostaseologie, 2019, 39(3): 238-249. DOI: 10.1055/s-0039-1683416.
[7] Herrera-Espejo S, Santos-Zorrozua B, Álvarez-González P, et al. A systematic review of microrna expression as biomarker of late-onset Alzheimer's disease [J]. Mol Neurobiol, 2019, 56(12): 8376-8391. DOI: 10.1007/s12035-019-01676-9.
[8] Organista-Juárez D, Jiménez A, Rocha L, et al. Differential expression of miR-34a, 449, 1260, 1275 and 1298 in the neocortex of patients with mesial temporal lobe epilepsy [J]. Epilepsy Res, 2019, 157(3): 106188. DOI: 10.1016/j.eplepsyres.2019.106188.
[9] Lyttle MD, Rainford NEA, Gamble C, et al. Levetiracetam versus phenytoin for second-line treatment of paediatric convulsive status epilepticus (EcLiPSE): a multicentre, open-label, randomised trial[J]. Lancet, 2019, 393(1): 2125-2134. doi: 10.1016/S0140-6736(19)30724-X.
[10] 申继亮,唐丹. 一般自我效能感量表(GSES)在老年人中的使用[J]. 中国临床心理学杂志,2004,12(4): 342-344. DOI: 10.3969/j.issn.1005-3611.2004.04.004.
[11] 任晓琳,梁平,刘雪琴. 癫痫患者生活质量量表-31(中文版)的翻译及修订[J]. 解放军护理杂志,2003,20(4): 99-101. DOI: 10.3969/j.issn.1008-9993.2003.04.065.
[12] 张鹏,杨菁菁,李晗郡. 血小板抗体筛查在DIC中的应用价值分析[J]. 标记免疫分析与临床,2019,26(6):1000-1003. DOI: 10.11748/bjmy.issn.1006-1703.2019.06.025.
[13] 郭凯,王笑欢,王孟键,等. 血小板减少患儿血小板抗体筛查及分析[J]. 中国输血杂志,2019,32(2): 99-102. DOI: 10.13303/j.cjbt.issn.1004-549x.2019.02.001.
[14] 谭茜茜,魏习薇,巩天祥,等. 血小板抗体筛查及交叉配型的临床应用[J]. 中国输血杂志,2021,34(4): 382-385. DOI: 10.13303/j.cjbt.issn.1004-549x.2021.04.014.
[15] 陆乐,李平,刘婷婷,等. 不同性别、临床科室患者血小板抗体筛查结果分析[J]. 国际检验医学杂志,2021,42(3): 263-265,269. DOI: 10.3969/j.issn.1673-4130.2021. 03.002.
[16] 李春晶,刘庆华,全传松,等. 重症发热伴血小板减少综合征临床特征研究[J]. 医学信息,2023,36(6): 172-175. DOI: 10.3969/j.issn.1006-1959.2023.06.039.
[17] 陈广,陈韬,舒赛男,等. 重症发热伴血小板减少综合征诊治专家共识[J]. 传染病信息,2022,35(5): 385-393. DOI: 10.3969/j.issn.1007-8134.2022.05.001.
[18] 苏学芳,靳爱华,宋红娥. 乐陵市2013-2020年发热伴血小板减少综合征的流行病学特点分析[J]. 临床医学,2022,42(3): 1-3. DOI: 10.19528/j.issn.1003-3548.2022.03.001.
[19] 严佳敏. 发热伴血小板减少综合征病毒感染宿主细胞的转录组学分析及诱导细胞自噬机制的研究[D]. 武汉:武汉大学,2022. DOI: 10.27379/d.cnki.gwhdu.2021.000919.
[20] 王永梅,郝淑卿,王鹏雁. 精准护理模式对发热伴血小板减少综合征患者的影响[J]. 齐鲁护理杂志,2020,26(15): 88-91. DOI: 10.3969/j.issn.1006-7256.2020.15.029.
|